+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Crohn`s Disease (CD) Therapy - Global Strategic Business Report

  • PDF Icon

    Report

  • 142 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309469
The global market for Crohn`s Disease (CD) Therapy was estimated at US$12.7 Billion in 2023, and is projected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Anti-TNF Biologics segment, which is expected to reach US$7.4 Billion by 2030 with a CAGR of a 5.8%. The Aminosalicyates segment is also set to grow at 2.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.5 Billion in 2023, and China, forecasted to grow at an impressive 4.5% CAGR to reach $2.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Crohn`s Disease (CD) Therapy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Crohn`s Disease (CD) Therapy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Crohn`s Disease (CD) Therapy Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Crohn`s Disease (CD) Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Crohn's Disease Drives Demand for Effective Therapies
  • Growing Awareness and Better Diagnostic Techniques Bolster Early Treatment Adoption
  • Expansion of Healthcare Infrastructure Supports Accessibility to Advanced CD Therapies
  • Emerging Markets Exhibit Increased Demand Due to Rising Healthcare Spending
  • Growing Demand for Non-Surgical Interventions Bolsters Non-Invasive Therapy Development
  • Shift Toward Combination Therapies Offers Comprehensive Disease Management
  • Nutritional Research Influences Adjunct Therapies in CD Treatment Regimens
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Aminosalicyates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Anti-TNF Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Anti-Integrin Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 22: World Crohn`s Disease (CD) Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
JAPAN
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
CHINA
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: China Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: China 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
EUROPE
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
FRANCE
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 41: France Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: France Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: France 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
GERMANY
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Germany Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Germany 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Italy Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Italy 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: UK Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: UK 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Rest of Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 59: Rest of World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Rest of World Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Rest of World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

Table Information